In Brief: Third Dose of mRNA-based COVID-19 Vaccines for Immunocompromised Persons
Date: September 20, 2021
Issue #:
1633Summary:
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA-based COVID-19 vaccines
manufactured by Pfizer/BioNTech(Comirnaty) and
Moderna(Spikevax) to include administration of a third
dose in persons ≥12 years old (Pfizer/BioNTech) or ≥18
years old (Moderna) who have undergone solid organ
transplantation or have a condition that compromises
the immune system to a similar extent (see Table 1).
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Source Type: research